Evidence map›Paper›PMID 35748124›Full record

ArticleEuropean journal of heart failure2022

Long-term survival and life expectancy following an acute heart failure hospitalization in Australia and New Zealand.

Saranya Hariharaputhiran, Yang Peng, Linh Ngo, Anna Ali, Sadia Hossain, Renuka Visvanathan, Robert Adams, Wandy Chan, Isuru Ranasinghe

Open access · hybridAbstract read
In one paragraph

Article in European journal of heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
8.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 54 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. 2024 update in heart failure.ESC heart failure · 2025
    Review
  14. Article
  15. Article
  16. Global epidemiology of heart failure.Nature reviews. Cardiology · 2024
    Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Saranya HariharaputhiranDepartment of Pharmacology, Pondicherry Institute of Medical Sciences, Puducherry, India.
Yang PengDepartment of Cardiology, The Prince Charles Hospital, Brisbane, QLD, Australia.
Linh NgoDepartment of Cardiology, The Prince Charles Hospital, Brisbane, QLD, Australia.
Anna AliDiscipline of Medicine, University of Adelaide, Adelaide, SA, Australia.
Sadia HossainSchool of Public Health, University of Adelaide, Adelaide, SA, Australia.
Renuka VisvanathanCollege of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.
Robert AdamsAdelaide Geriatrics Training and Research with Aged Care (GTRAC) Centre, Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia.
Wandy ChanDepartment of Cardiology, The Prince Charles Hospital, Brisbane, QLD, Australia.
Isuru RanasingheDepartment of Cardiology, The Prince Charles Hospital, Brisbane, QLD, Australia.
Prince Charles Hospital · AUUniversity of Adelaide · AUBasil Hetzel Institute · AUPondicherry Institute of Medical Sciences · INUniversity of Queensland · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsContemporary long-term survival following a heart failure (HF) hospitalization is uncertain. We evaluated survival up to 10 years after a HF hospitalization using national data from Australia and New Zealand, identified predictors of survival, and estimated the attributable loss in life expectancy. METHODS AND

resultsPatients hospitalized with a primary diagnosis of HF from 2008-2017 were identified and all-cause mortality assessed by linking with Death Registries. Flexible parametric survival models were used to estimate survival, predictors of survival and loss in life expectancy. A total of 283 048 patients with HF were included (mean age 78.2 ± 12.3 years, 50.8% male). Of these, 48.3% (48.1-48.5) were surviving by 3 years, 34.1% (33.9-34.3) by 5 years and 17.1% (16.8-17.4) by 10 years (median survival 2.8 years). Survival declined with age with 53.4% of patients aged 18-54 years and 6.2% aged ≥85 years alive by 10 years (adjusted hazard ratio [aHR] for mortality 4.84, 95% confidence interval [CI] 4.65-5.04 for ≥85 years vs. 18-54 years) and was worse in male patients (aHR 1.14, 95% CI 1.13-1.15). Prior HF (aHR 1.20, 95% CI 1.18-1.22), valvular and rheumatic heart disease (aHR 1.11, 95% CI 1.10-1.13) and vascular disease (aHR 1.07, 95% CI 1.04-1.09) were cardiovascular comorbidities most strongly associated with long-term death. Non-cardiovascular comorbidities and geriatric syndromes were common and associated with higher mortality. Compared with the general population, HF was associated with a loss of 7.3 years in life expectancy (or 56.6% of the expected life expectancy) and reached 20.5 years for those aged 18-54 years.

conclusionLess than one in five patients hospitalized for HF were surviving by 10 years with patients experiencing almost 60% loss in life expectancy compared with the general population, highlighting the considerable persisting societal burden of HF. Concerted multidisciplinary efforts are needed to improve post-hospitalization outcomes of HF.

Indexed as

Heart FailureAgedAged, 80 and overAustraliaFemaleHospitalizationHumansLife ExpectancyMaleNew ZealandHeart failureHospitalizationsMortalityOutcomesPrognosisSurvival

Identifiers

PMID35748124
PMCPMC9804480
OpenAlexW4283379080

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.